The collaboration combines ProMed’s micromolding and extrusion capabilities with DSM’s biomedical polyurethanes, polyurethaneureas, and bioerodible amino-acid-based polyesteramides. The goal is the development of novel sustained release drug implants and combination devices, the companies said in an announcement in January.
Both companies say they have experience helping both established and early-stage medical device and pharmaceutical companies develop material formulations, manufacturing processes and platforms for controlled release of drugs.
“ProMed and DSM have been working together on novel drug delivery technologies for many years and we look forward to leveraging our respective capabilities to cooperate more closely on projects of mutual interest,” said James Arps, director of pharma services at ProMed Pharma. Based outside Minneapolis, ProMed Pharma ProMed Pharma grew out of work at its sister company ProMed Molded Products — which is focused on the molding of small, intricately designed silicone and thermoplastic components and sub-assemblies.
Marc Hendriks, head of strategy and alliances at Exton, Pa.–based DSM, spoke of long-term collaboration leading to joint success.